Pediatrix Medical Group's revenue for the
three
months ended in Mar. 2026 was €412 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was €1,660 Mil.
Pediatrix Medical Group's Revenue per Share for the
three
months ended in Mar. 2026 was €4.96.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €19.54.
Warning Sign:
Pediatrix Medical Group Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of Pediatrix Medical Group was -3.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -1.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 1.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -3.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Pediatrix Medical Group's highest 3-Year average Revenue per Share Growth Rate was 72.80% per year. The lowest was -15.90% per year. And the median was 12.80% per year.
Pediatrix Medical Group (FRA:PDC) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Pediatrix Medical Group's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pediatrix Medical Group Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's Revenue distribution charts can be found below:
* The bar in red indicates where Pediatrix Medical Group's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,660 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pediatrix Medical Group (FRA:PDC) has a Revenue of €1,660 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Pediatrix Medical Group and its competitors.
Is Pediatrix Medical Group's Revenue too high?
Pediatrix Medical Group's current Revenue is €1,660 Mil. Overall, Pediatrix Medical Group has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's Revenue compare to SEM and AGL?
Pediatrix Medical Group's Revenue of €1,660 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Pediatrix Medical Group and its competitors. Pediatrix Medical Group's current Revenue is €1,660 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Pediatrix Medical Group (FRA:PDC) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.66, compared to a current price of €23.80 — trading 104.1% above its estimated fair value. The current Revenue is €1,660 Mil. Pediatrix Medical Group's overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current Revenue is €1,660 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?
Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued.
The current stock price of €23.80 is trading 104.1% above its estimated GF Value™ of €11.66.
GuruFocus considers Pediatrix Medical Group to be Significantly Overvalued.
Key valuation signals for FRA:PDC:
Revenue: €1,660 Mil
GF Value™: €11.66 vs. price of €23.80 (104.1% above fair value)
No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
57GF Score
Get the complete analysis for FRA:PDC
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:PDC has been successfully added to your 
